The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in cardiovascular care.
An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback